moexipril (Rx)

Brand and Other Names:Univasc
  • Print

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

tablet

  • 7.5mg
  • 15mg
more...

Hypertension

Initial: 7.5mg PO qDay 1 hour prior to meal, OR 3.75mg PO qDay if on thiazide diuretc

Maintenance: 7.5-30 mg/day PO qDay or divided q12hr

Administer 1 hr before meals

Renal Impairment

CrCl <40 mL/min: Initial 3.75 mg PO qDay, no more than 15 mg/day

Dosing Considerations

Beneficial for many patients at risk for heart disease; reduces risk of MI, stroke, diabetic nephropathy , microalbuminuria, new onset DM

Consider starting an ACE inhibitor in high-risk patients, even if no HTN or CHF

May prolong survival in CHF, may preserve renal function in DM

May help to prevent migraine HA

Good choice in hyperlipidemia patients

Requires weeks for full effect; to start, use low dose and titrate q1-2wk

Abrupt discontinuance not associated with rapid increase in BP

Safety and efficacy not established

Next:

Interactions

Interaction Checker

and moexipril

No Results

     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            All Interactions Sort By:
             activity indicator 
            Previous
            Next:

            Adverse Effects

            1-10%

            Dizziness

            Hypotension

            Peripheral edema

            Cough

            Headache

            Myalgia

            Polyuria

            Hyponatremia

            Pharyngitis

            Sinusitis

            Rash

            Nausea/vomiting

            Hyperkalemia

            Hyponatremia

            Frequency Not Defined

            Angioedema

            Arrhythmia

            Chest pain

            Pneumonitis

            Syncope

            Proteinuria

            Agranulocytosis (esp. if pt has CVD with or without renal impairment)

            Hepatic failure (rare)

            Renal failure

            Previous
            Next:

            Warnings

            Black Box Warnings

            Discontinue as soon as possible when pregnancy is detected; affects renin-angiotensin system causing oligohydramnios, which may result in fetal injury and/or death

            Contraindications

            Hypersensitivity to moexipril/other ACE inhibitors

            History of hereditary or angioedema associated with previous ACE inhibitor treatment

            Bilateral renal artery stenosis

            Do not coadminister with aliskiren in patients with diabetes mellitus or with renal impairment (ie, GFR <60 mL/min/1.73 m²)

            Pregnancy (2nd and 3rd trimesters): significant risk of fetal/neonatal morbidity and mortality

            Cautions

            Apheresis (LDL) with dextran sulfate, hypertrophic cardiomyopathy, collagen vascular dz, hemodialysis with high flux membrane, arotic stenosis

            Less effective in African-Americans

            Excessive hypotension if concomitant diuretics, hypovolemia, hyponatremia

            Risk of hyperkalemia, especially with renal impairment, DM, or those taking concomitant K+-elevating drugs

            Dual blockade of the renin angiotensin system with ARBs, ACE inhibitors, or aliskiren associated with increased risk for hypotension, hyperkalemia, and renal function changes (including acute renal failure) compared to monotherapy

            ACE inhibition also causes increased bradykinin levels which putatively mediates angioedema

            Coadministration with mTOR inhibitors (eg, temsirolimus) may increased risk for angioedema

            Renal impairment may occur

            Neutropenia/agranulocytosis reported

            Cough may occur within the first few months

            Cholestatic jaundice may occur

            Use caution in severe aortic stenosis  

            Discontinue immediately if pregnant (see Contraindications and Black Box Warnings)

            Renal impairment

            Previous
            Next:

            Pregnancy & Lactation

            Pregnancy Category: C (1st trimester); D (2nd & 3rd trimesters)

            Discontinue as soon as pregnancy detected; during the second and third trimesters of pregnancy, drugs that act directly on the renin-angiotensin have been associated with fetal injury that includes hypotension, neonatal skull hypoplasia, anuria, reversible or irreversible renal failure, and death

            Lactation: not known if excreted into breast milk; use caution

            Pregnancy Categories

            A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

            B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

            C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

            D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

            X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

            NA:Information not available.

            more...
            Previous
            Next:

            Pharmacology

            Mechanism of Action

            Angiotensin converting enzyme (ACE) inhibitors dilate arteries and veins by competively inhibiting the conversion of angiotensin I to angiotensin II (a potent endogenous vasoconstrictor) and by inhibiting bradykinin metabolism; these actions result in preload and afterload reductions on the heart

            ACE inhibitors also promote sodium and water excretion by inhibiting angiotensin-II induced aldosterone secretion; elevation in potassium may also be observed

            ACE inhibitors also elicit renoprotective effects through vasodilation of renal arterioles

            ACE inhibitors reduce cardiac and vascular remodeling associated with chronic hypertension, heart failure, and myocardial infarction

            Pharmacokinetics

            Half-Life: 1 hr (moexepril); 2-9 hr (moexiprilat)

            Duration: 24 hr

            Onset: 1-2 hr (peak effect)

            Total Body Clearance: 441 mL/min (Moexipril); 223 mL/min (moexiprilat)

            Excretion: Feces (50%); urine (13%)

            Peak Plasma Time: 1.5 hr

            Bioavailability: 13-22%

            Protein Bound: 90% (moexepril); 50-70% (moexeprilat)

            Vd: 180 L

            Metabolism: extensively metabolized in liver, minimally metabolized at intestinal wall

            Metabolites: Moexiprilat (active)

            Previous
            Next:

            Images

            Previous
            Next:

            Formulary

            FormularyPatient Discounts

            Adding plans allows you to compare formulary status to other drugs in the same class.

            To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

            Adding plans allows you to:

            • View the formulary and any restrictions for each plan.
            • Manage and view all your plans together – even plans in different states.
            • Compare formulary status to other drugs in the same class.
            • Access your plan list on any device – mobile or desktop.

            The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

            Tier Description
            1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
            2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
            3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
            4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            NC NOT COVERED – Drugs that are not covered by the plan.
            Code Definition
            PA Prior Authorization
            Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
            QL Quantity Limits
            Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
            ST Step Therapy
            Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
            OR Other Restrictions
            Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
            Additional Offers
            Email to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Email Forms to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Previous